You just read:

BIAL and Eisai Announce New Data That Once-daily Zebinix® (eslicarbazepine acetate) Monotherapy is Effective and Well Tolerated According to First Data Presented at the American Academy of Neurology (AAN) Annual Meeting

News provided by

Eisai

18 Apr, 2016, 00:01 BST